A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Sponsor: |
Advenchen Laboratories, LLC. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS0001 |
U.S. Govt. ID: |
NCT03016819 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The researchers hope to study the effectiveness of an investigational drug called AL3818 in people who have metastatic (meaning their disease has spread) or advanced ), specifically alveolar soft partsarcoma (ASPS), leiomyosarcoma (LMS) and synovial sarcoma (SS). The main purpose of the study isto learn the percentage of patients that respond to treatment with AL3818 if you have ASPS or if AL3818 delays the time until cancer worsens when compared to another drug called dacarbazine if a person has either LMS or SS. Other purposes of the study are to learn how long people respond to AL3818, if AL3818 extends overall survival and the safety of AL3818.
This study is closed
Investigator
Matthew Ingham, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have a life expectancy of at least 3 months? |
Yes |
No |
Have you been diagnosed with metastatic (disease has spread) or locally advanced sarcoma? |
Yes |
No |
Did your disease get worse after the last time you received standard therapy? |
Yes |
No |